EUCOPE gives voice to small to medium-sized innovative companies active in the field of pharmaceuticals, biotechnologies, and medical technologies at the European level. Learn more about the benefits of membership with EUCOPE.
It is the organisation that represents companies like PTC – relentlessly innovative, typically smaller in size and focused on developing therapies for people with rare diseases. There are many important legislative and policy discussions going on which will shape the healthcare sector in general and the biopharmaceutical industry, in particular for, years to come. EUCOPE ensures very effectively that the voices, opinions and expertise of PTC and others are heard.
Through our membership of EUCOPE, we’ve been able to far more effectively understand, follow and contribute to areas important to our patients, our business and our industry sector.
Over the years, we have come to appreciate the quality of your support – both from a strategic and day-to-day, tactical perspective – as well as the tailored attention that your leadership and staff continuously pay to any of your members, large or small, especially as you accomplish your mission of guiding us through often complex EU legislative processes and political decisions and of raising the attractiveness of Europe for our industry.
EUCOPE provides expert intelligence to its members, enabling us to stay on top of the latest policy issues, as well as valuable networking opportunities. EUCOPE is a strong voice for industry to when communicating the value that companies bring to health systems across Europe and globally.
EUCOPE provides a platform for discussions on major healthcare topics and developments. Your ad hoc expertise on national market access issues, as well your close relationship with many national medicines and HTA agencies in Europe, are particularly useful for us, and I’m sure for many of the other members.
We believe that EUCOPE’s mission to facilitate trusted relationships with established stakeholders at the EU and national levels and giving greater voice to companies regardless of their size is very important to enabling innovation and the creation of synergies for the benefit of patients.
What is unique about EUCOPE is that it provides the perfect mix of EU affairs and country perspectives. We appreciate EUCOPE’s willingness to explore new areas of engagement if it is important to its member companies as well as the swift and agile way it operates.
We see EUCOPE as an important advocate on policy issues for our industry in Brussels and a critical voice that represents small, medium, and global companies. Having EUCOPE champion the cutting-edge research and inherent risk-taking innovation required by our industry with policymakers helps to promote well-balanced policy proposals that allow all aspects of our industry to flourish.
As a specialized biotherapeutics company, we specifically value EUCOPE’s network and trusted relationships with established stakeholders at the EU and national levels to connect and share experiences with the European Commission, the European Parliament, Member States’ representatives, patient organizations, healthcare professionals and payers, academics, and other industry associations.
EUCOPE’s successful intervention on behalf of its members and the broader life sciences industry with stakeholders spanning policymakers, payers, and influencers is unparalleled. MAP has proudly supported EUCOPE throughout our 10 years including many joint webinars and representation in payer meetings such as NICE, and we look forward to many more.
MAP Patient Access
One distinct feature of EUCOPE is its country and market access focus and expertise. Another one is its bottom-up approach and willingness to be innovation-driven before consensus-driven and allowing any of its members regardless of its size to bring forward an idea or project.
Two significant advantages of working with EUCOPE are their deep understanding of country reimbursement pathways for advanced pharmaceutical and medical technologies – enabling sharing of learnings across orphan medicines, gene therapies and advanced diagnostics; secondly, their operating model and relationships with national biotech and diagnostic organisations enables flexible engagement with national, as well as EU decision-makers.
EUCOPE really helps us to keep an eye on European developments and to give a voice to companies that are mid-sized (for now) and follow their passion to serve patients more than shareholder-driven profits.
Sitting together with many sector-mates, listening to their experiences, sharing best practices, and being part of a lobby association aimed at making pharma innovation advance meaningfully for the best of the patients, is what made Ferrer want to be part of EUCOPE.
We consider EUCOPE to be among the few European trade associations which are 100% committed to representing the voices of small to mid-sized companies working in the field of rare diseases. Many of the working groups which EUCOPE has created, such as the Incentives Steering Group (ISG) or the EU HTA Task Force are led by professional and dedicated EUCOPE employees which makes the work pleasant and the deliverables impactful.
Sobi - Swedish Orphan Biovitrum
We became a member of EUCOPE as we wanted to find the right organisation to represent small-size companies like Enterome at the EU level as well as have the possibility to join working groups and have an impact, through EUCOPE, on upcoming EU legislative framework.
Given the typical challenges around patient access inherent to rare disease therapies, we highly value the focus and rich expertise of EUCOPE in country and market access policy, and its well-established relationships with national and EU decision-makers that provide a conduit for our perspectives. In addition, utilising its portfolio of membership services and tools has helped us to stay current on relevant European and national policy.
We wanted to join a trade association that understands and supports a clinical-stage biotechnology company as we build our presence in Europe in voicing our opinions and/or concerns on topics such as the transition into CTIS, orphan medicine landscape and regulatory pathways such as PRIME and Conditional Marketing Authorisation (CMA).
As a new company building our presence in Europe, we wanted to join a trade association that understands the challenges of small and medium-size biopharmaceutical companies. We were attracted to EUCOPE because it has an established record of representing the interests of companies like ours with key stakeholders in Brussels. We look forward to being an active participant and working with EUCOPE to help navigate the changing regulatory and access environment in Europe.
We have joined EUCOPE because we share its vision of a Europe where patients have access to the best possible care through innovation in the life sciences sector. We also appreciate its role in representing and engaging with European institutions, national authorities, patient associations, and other stakeholders in the sector.
Stay in touch
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View